Annual report
8086.TEDINET S100R5KJ
Period2022-04-01 → 2023-03-31
Filed2023-06-28
StandardJapan GAAP
ConsolidatedYes
Data checks24 of 24 passed
Key figures · 154
| Metric | Value | Period | Scope | Source row |
|---|---|---|---|---|
| Revenue | ¥545.2bn | 2022-04-01 → 2023-03-31 | Cons. | Net sales |
| Revenue | ¥494.8bn | 2021-04-01 → 2022-03-31 | Cons. | Net sales |
| Revenue | ¥455.6bn | 2020-04-01 → 2021-03-31d | Cons. | Net sales (5-year summary) |
| Revenue | ¥442.5bn | 2019-04-01 → 2020-03-31d | Cons. | Net sales (5-year summary) |
| Revenue | ¥426.4bn | 2018-04-01 → 2019-03-31d | Cons. | Net sales (5-year summary) |
| Operating income | ¥17.7bn | 2022-04-01 → 2023-03-31 | Cons. | Operating income |
| Operating income | ¥23.9bn | 2021-04-01 → 2022-03-31 | Cons. | Operating income |
| Ordinary income | ¥15.3bn | 2022-04-01 → 2023-03-31 | Cons. | Ordinary income |
| Ordinary income | ¥27.6bn | 2021-04-01 → 2022-03-31 | Cons. | Ordinary income |
| Ordinary income | ¥26.3bn | 2020-04-01 → 2021-03-31d | Cons. | Ordinary income loss (5-year summary) |
| Ordinary income | ¥23.4bn | 2019-04-01 → 2020-03-31d | Cons. | Ordinary income loss (5-year summary) |
| Ordinary income | ¥22.4bn | 2018-04-01 → 2019-03-31d | Cons. | Ordinary income loss (5-year summary) |
| Profit before tax | ¥16.8bn | 2022-04-01 → 2023-03-31 | Cons. | Income before income taxes |
| Profit before tax | ¥23.2bn | 2021-04-01 → 2022-03-31 | Cons. | Income before income taxes |
| Net income (owners) | ¥4.6bn | 2022-04-01 → 2023-03-31 | Cons. | Profit loss attributable to owners of parent |
| Net income (owners) | ¥13.5bn | 2021-04-01 → 2022-03-31 | Cons. | Profit loss attributable to owners of parent |
| Net income (owners) | ¥14.2bn | 2020-04-01 → 2021-03-31d | Cons. | Profit loss attributable to owners of parent (5-year summary) |
| Net income (owners) | −¥12.3bn | 2019-04-01 → 2020-03-31d | Cons. | Profit loss attributable to owners of parent (5-year summary) |
| Net income (owners) | ¥12.1bn | 2018-04-01 → 2019-03-31d | Cons. | Profit loss attributable to owners of parent (5-year summary) |
| Net income | ¥5.9bn | 2022-04-01 → 2023-03-31 | Cons. | Profit loss |
| Net income | ¥15.1bn | 2021-04-01 → 2022-03-31 | Cons. | Profit loss |
| Total assets | ¥1.03T | at 2023-03-31 | Cons. | Assets |
| Total assets | ¥930.3bn | at 2022-03-31 | Cons. | Assets |
| Total assets | ¥854.4bn | at 2021-03-31d | Cons. | Total assets (5-year summary) |
| Total assets | ¥831.9bn | at 2020-03-31d | Cons. | Total assets (5-year summary) |
| Total assets | ¥845.8bn | at 2019-03-31d | Cons. | Total assets (5-year summary) |
| Total liabilities | ¥785.2bn | at 2023-03-31 | Cons. | Liabilities |
| Total liabilities | ¥730.5bn | at 2022-03-31 | Cons. | Liabilities |
| Net assets / equity | ¥242.2bn | at 2023-03-31 | Cons. | Net assets |
| Net assets / equity | ¥199.9bn | at 2022-03-31 | Cons. | Net assets |
| Net assets / equity | ¥174.1bn | at 2021-03-31d | Cons. | Net assets |
| Net assets / equity | ¥161.2bn | at 2020-03-31d | Cons. | Net assets (5-year summary) |
| Net assets / equity | ¥171.8bn | at 2019-03-31d | Cons. | Net assets (5-year summary) |
| Cash and deposits | ¥89.7bn | at 2023-03-31 | Cons. | Cash and deposits |
| Cash and deposits | ¥95.3bn | at 2022-03-31 | Cons. | Cash and deposits |
| Cash & equivalents | ¥84.7bn | at 2023-03-31 | Cons. | Cash and cash equivalents |
| Cash & equivalents | ¥90.1bn | at 2022-03-31 | Cons. | Cash and cash equivalents |
| Cash & equivalents | ¥85.8bn | at 2021-03-31d | Cons. | Cash and cash equivalents |
| Cash & equivalents | ¥90.2bn | at 2020-03-31d | Cons. | Cash and cash equivalents (5-year summary) |
| Cash & equivalents | ¥120.3bn | at 2019-03-31d | Cons. | Cash and cash equivalents (5-year summary) |
| Operating cash flow | ¥10.4bn | 2022-04-01 → 2023-03-31 | Cons. | Net cash provided by used in operating activities |
| Operating cash flow | ¥68.2bn | 2021-04-01 → 2022-03-31 | Cons. | Net cash provided by used in operating activities |
| Operating cash flow | ¥66.1bn | 2020-04-01 → 2021-03-31d | Cons. | Net cash provided by used in operating activities (5-year summary) |
| Operating cash flow | ¥37.2bn | 2019-04-01 → 2020-03-31d | Cons. | Net cash provided by used in operating activities (5-year summary) |
| Operating cash flow | ¥41.4bn | 2018-04-01 → 2019-03-31d | Cons. | Net cash provided by used in operating activities (5-year summary) |
| Investing cash flow | −¥71.7bn | 2022-04-01 → 2023-03-31 | Cons. | Net cash provided by used in investment activities |
| Investing cash flow | −¥78.4bn | 2021-04-01 → 2022-03-31 | Cons. | Net cash provided by used in investment activities |
| Investing cash flow | −¥45.1bn | 2020-04-01 → 2021-03-31d | Cons. | Net cash provided by used in investing activities (5-year summary) |
| Investing cash flow | −¥58.3bn | 2019-04-01 → 2020-03-31d | Cons. | Net cash provided by used in investing activities (5-year summary) |
| Investing cash flow | −¥64.7bn | 2018-04-01 → 2019-03-31d | Cons. | Net cash provided by used in investing activities (5-year summary) |
| Financing cash flow | ¥43.1bn | 2022-04-01 → 2023-03-31 | Cons. | Net cash provided by used in financing activities |
| Financing cash flow | ¥10.3bn | 2021-04-01 → 2022-03-31 | Cons. | Net cash provided by used in financing activities |
| Financing cash flow | −¥22.1bn | 2020-04-01 → 2021-03-31d | Cons. | Net cash provided by used in financing activities (5-year summary) |
| Financing cash flow | −¥4.6bn | 2019-04-01 → 2020-03-31d | Cons. | Net cash provided by used in financing activities (5-year summary) |
| Financing cash flow | ¥12.6bn | 2018-04-01 → 2019-03-31d | Cons. | Net cash provided by used in financing activities (5-year summary) |
| EPS (basic) | ¥28.05 | 2022-04-01 → 2023-03-31 | Cons. | Basic earnings loss per share (5-year summary) |
| EPS (basic) | ¥82.5 | 2021-04-01 → 2022-03-31 | Cons. | Basic earnings loss per share (5-year summary) |
| EPS (basic) | ¥87.12 | 2020-04-01 → 2021-03-31d | Cons. | Basic earnings loss per share (5-year summary) |
| EPS (basic) | ¥-75.3 | 2019-04-01 → 2020-03-31d | Cons. | Basic earnings loss per share (5-year summary) |
| EPS (basic) | ¥73.68 | 2018-04-01 → 2019-03-31d | Cons. | Basic earnings loss per share (5-year summary) |
| EPS (diluted) | ¥24.85 | 2022-04-01 → 2023-03-31 | Cons. | Diluted earnings per share (5-year summary) |
| EPS (diluted) | ¥77.42 | 2021-04-01 → 2022-03-31 | Cons. | Diluted earnings per share (5-year summary) |
| EPS (diluted) | ¥66.75 | 2018-04-01 → 2019-03-31d | Cons. | Diluted earnings per share (5-year summary) |
| Net assets per share | ¥1,265 | at 2023-03-31 | Cons. | Net assets per share (5-year summary) |
| Net assets per share | ¥1,135.76 | at 2022-03-31 | Cons. | Net assets per share (5-year summary) |
| Net assets per share | ¥987.3 | at 2021-03-31d | Cons. | Net assets per share (5-year summary) |
| Net assets per share | ¥912.24 | at 2020-03-31d | Cons. | Net assets per share (5-year summary) |
| Net assets per share | ¥990.14 | at 2019-03-31d | Cons. | Net assets per share (5-year summary) |
| Equity ratio | 20.1% | at 2023-03-31 | Cons. | Equity to asset ratio (5-year summary) |
| Equity ratio | 19.9% | at 2022-03-31 | Cons. | Equity to asset ratio (5-year summary) |
| Equity ratio | 18.8% | at 2021-03-31d | Cons. | Equity to asset ratio (5-year summary) |
| Equity ratio | 17.9% | at 2020-03-31d | Cons. | Equity to asset ratio (5-year summary) |
| Equity ratio | 19.1% | at 2019-03-31d | Cons. | Equity to asset ratio (5-year summary) |
| ROE | 2.3% | 2022-04-01 → 2023-03-31 | Cons. | Rate of return on equity (5-year summary) |
| ROE | 7.8% | 2021-04-01 → 2022-03-31 | Cons. | Rate of return on equity (5-year summary) |
| ROE | 9.2% | 2020-04-01 → 2021-03-31d | Cons. | Rate of return on equity (5-year summary) |
| ROE | -7.9% | 2019-04-01 → 2020-03-31d | Cons. | Rate of return on equity (5-year summary) |
| ROE | 7.3% | 2018-04-01 → 2019-03-31d | Cons. | Rate of return on equity (5-year summary) |
| Employees | 38,770 | at 2023-03-31 | Cons. | Number of employees |
| Employees | 36,259 | at 2022-03-31 | Cons. | Number of employees |
| Employees | 35,251 | at 2021-03-31d | Cons. | Number of employees |
| Employees | 32,786 | at 2020-03-31d | Cons. | Number of employees |
| Employees | 29,325 | at 2019-03-31d | Cons. | Number of employees |
| Revenue | ¥349.7bn | 2022-04-01 → 2023-03-31 | Standalone | Net sales |
| Revenue | ¥331.2bn | 2021-04-01 → 2022-03-31 | Standalone | Net sales |
| Revenue | ¥334.9bn | 2020-04-01 → 2021-03-31d | Standalone | Net sales (5-year summary) |
| Revenue | ¥340.8bn | 2019-04-01 → 2020-03-31d | Standalone | Net sales (5-year summary) |
| Revenue | ¥310.6bn | 2018-04-01 → 2019-03-31d | Standalone | Net sales (5-year summary) |
| Operating income | ¥3.3bn | 2022-04-01 → 2023-03-31 | Standalone | Operating income |
| Operating income | ¥11.6bn | 2021-04-01 → 2022-03-31 | Standalone | Operating income |
| Ordinary income | ¥8.7bn | 2022-04-01 → 2023-03-31 | Standalone | Ordinary income |
| Ordinary income | ¥17.5bn | 2021-04-01 → 2022-03-31 | Standalone | Ordinary income |
| Ordinary income | ¥16.5bn | 2020-04-01 → 2021-03-31d | Standalone | Ordinary income loss (5-year summary) |
| Ordinary income | ¥16.1bn | 2019-04-01 → 2020-03-31d | Standalone | Ordinary income loss (5-year summary) |
| Ordinary income | ¥17.4bn | 2018-04-01 → 2019-03-31d | Standalone | Ordinary income loss (5-year summary) |
| Profit before tax | ¥11.6bn | 2022-04-01 → 2023-03-31 | Standalone | Income before income taxes |
| Profit before tax | ¥14.7bn | 2021-04-01 → 2022-03-31 | Standalone | Income before income taxes |
| Net income | ¥8.7bn | 2022-04-01 → 2023-03-31 | Standalone | Profit loss |
| Net income | ¥10.7bn | 2021-04-01 → 2022-03-31 | Standalone | Profit loss |
| Net income | ¥9.7bn | 2020-04-01 → 2021-03-31d | Standalone | Net income loss (5-year summary) |
| Net income | −¥16.4bn | 2019-04-01 → 2020-03-31d | Standalone | Net income loss (5-year summary) |
| Net income | ¥12.2bn | 2018-04-01 → 2019-03-31d | Standalone | Net income loss (5-year summary) |
| Total assets | ¥764.9bn | at 2023-03-31 | Standalone | Assets |
| Total assets | ¥727.0bn | at 2022-03-31 | Standalone | Assets |
| Total assets | ¥695.1bn | at 2021-03-31d | Standalone | Total assets (5-year summary) |
| Total assets | ¥666.1bn | at 2020-03-31d | Standalone | Total assets (5-year summary) |
| Total assets | ¥654.7bn | at 2019-03-31d | Standalone | Total assets (5-year summary) |
| Total liabilities | ¥583.3bn | at 2023-03-31 | Standalone | Liabilities |
| Total liabilities | ¥547.2bn | at 2022-03-31 | Standalone | Liabilities |
| Net assets / equity | ¥181.6bn | at 2023-03-31 | Standalone | Net assets |
| Net assets / equity | ¥179.7bn | at 2022-03-31 | Standalone | Net assets |
| Net assets / equity | ¥173.7bn | at 2021-03-31d | Standalone | Net assets |
| Net assets / equity | ¥157.7bn | at 2020-03-31d | Standalone | Net assets (5-year summary) |
| Net assets / equity | ¥171.0bn | at 2019-03-31d | Standalone | Net assets (5-year summary) |
| Cash and deposits | ¥7.6bn | at 2023-03-31 | Standalone | Cash and deposits |
| Cash and deposits | ¥7.1bn | at 2022-03-31 | Standalone | Cash and deposits |
| EPS (basic) | ¥53.47 | 2022-04-01 → 2023-03-31 | Standalone | Basic earnings loss per share (5-year summary) |
| EPS (basic) | ¥65.87 | 2021-04-01 → 2022-03-31 | Standalone | Basic earnings loss per share (5-year summary) |
| EPS (basic) | ¥59.72 | 2020-04-01 → 2021-03-31d | Standalone | Basic earnings loss per share (5-year summary) |
| EPS (basic) | ¥-100.66 | 2019-04-01 → 2020-03-31d | Standalone | Basic earnings loss per share (5-year summary) |
| EPS (basic) | ¥74.25 | 2018-04-01 → 2019-03-31d | Standalone | Basic earnings loss per share (5-year summary) |
| EPS (diluted) | ¥47.38 | 2022-04-01 → 2023-03-31 | Standalone | Diluted earnings per share (5-year summary) |
| EPS (diluted) | ¥61.82 | 2021-04-01 → 2022-03-31 | Standalone | Diluted earnings per share (5-year summary) |
| EPS (diluted) | ¥67.27 | 2018-04-01 → 2019-03-31d | Standalone | Diluted earnings per share (5-year summary) |
| Dividend per share | ¥22 | 2022-04-01 → 2023-03-31 | Standalone | Dividend paid per share (5-year summary) |
| Dividend per share | ¥27 | 2021-04-01 → 2022-03-31 | Standalone | Dividend paid per share (5-year summary) |
| Dividend per share | ¥28 | 2020-04-01 → 2021-03-31d | Standalone | Dividend paid per share (5-year summary) |
| Dividend per share | ¥13.5 | 2019-04-01 → 2020-03-31d | Standalone | Dividend paid per share (5-year summary) |
| Dividend per share | ¥28 | 2018-04-01 → 2019-03-31d | Standalone | Dividend paid per share (5-year summary) |
| Net assets per share | ¥1,113.64 | at 2023-03-31 | Standalone | Net assets per share (5-year summary) |
| Net assets per share | ¥1,102.07 | at 2022-03-31 | Standalone | Net assets per share (5-year summary) |
| Net assets per share | ¥1,065.15 | at 2021-03-31d | Standalone | Net assets per share (5-year summary) |
| Net assets per share | ¥966.84 | at 2020-03-31d | Standalone | Net assets per share (5-year summary) |
| Net assets per share | ¥1,048.54 | at 2019-03-31d | Standalone | Net assets per share (5-year summary) |
| Equity ratio | 23.7% | at 2023-03-31 | Standalone | Equity to asset ratio (5-year summary) |
| Equity ratio | 24.7% | at 2022-03-31 | Standalone | Equity to asset ratio (5-year summary) |
| Equity ratio | 25.0% | at 2021-03-31d | Standalone | Equity to asset ratio (5-year summary) |
| Equity ratio | 23.7% | at 2020-03-31d | Standalone | Equity to asset ratio (5-year summary) |
| Equity ratio | 26.1% | at 2019-03-31d | Standalone | Equity to asset ratio (5-year summary) |
| ROE | 4.8% | 2022-04-01 → 2023-03-31 | Standalone | Rate of return on equity (5-year summary) |
| ROE | 6.1% | 2021-04-01 → 2022-03-31 | Standalone | Rate of return on equity (5-year summary) |
| ROE | 5.9% | 2020-04-01 → 2021-03-31d | Standalone | Rate of return on equity (5-year summary) |
| ROE | -10.0% | 2019-04-01 → 2020-03-31d | Standalone | Rate of return on equity (5-year summary) |
| ROE | 7.1% | 2018-04-01 → 2019-03-31d | Standalone | Rate of return on equity (5-year summary) |
| Shares issued | 171,459,000 | at 2023-03-31 | Standalone | Total number of issued shares (5-year summary) |
| Shares issued | 171,459,000 | at 2022-03-31 | Standalone | Total number of issued shares (5-year summary) |
| Shares issued | 171,459,000 | at 2021-03-31d | Standalone | Total number of issued shares (5-year summary) |
| Shares issued | 171,459,000 | at 2020-03-31d | Standalone | Total number of issued shares (5-year summary) |
| Shares issued | 171,459,000 | at 2019-03-31d | Standalone | Total number of issued shares (5-year summary) |
| Employees | 4,390 | at 2023-03-31 | Standalone | Number of employees |
| Employees | 4,252 | at 2022-03-31 | Standalone | Number of employees |
| Employees | 4,150 | at 2021-03-31d | Standalone | Number of employees |
| Employees | 4,060 | at 2020-03-31d | Standalone | Number of employees |
| Employees | 3,893 | at 2019-03-31d | Standalone | Number of employees |
Periods use the dates stated in the filing. d = earlier-year period dated by calendar; v = that date confirmed by the company's own earlier filing.
Segments · 103
| Segment | Item | Period | Value |
|---|---|---|---|
| Operating Segments Not Included In Reportable Segments And Other Revenue Generating Business Activitiesother segments | capex | 2022-04-01 → 2023-03-31 | ¥365m |
| Operating Segments Not Included In Reportable Segments And Other Revenue Generating Business Activitiesother segments | depreciation | 2022-04-01 → 2023-03-31 | ¥339m |
| Operating Segments Not Included In Reportable Segments And Other Revenue Generating Business Activitiesother segments | employees | at 2023-03-31 | 118 pure |
| Operating Segments Not Included In Reportable Segments And Other Revenue Generating Business Activitiesother segments | revenue | 2022-04-01 → 2023-03-31 | ¥4.4bn |
| Operating Segments Not Included In Reportable Segments And Other Revenue Generating Business Activitiesother segments | revenue external | 2022-04-01 → 2023-03-31 | ¥752m |
| Operating Segments Not Included In Reportable Segments And Other Revenue Generating Business Activitiesother segments | revenue intersegment | 2022-04-01 → 2023-03-31 | ¥3.7bn |
| Operating Segments Not Included In Reportable Segments And Other Revenue Generating Business Activitiesother segments | segment assets | at 2023-03-31 | ¥201.7bn |
| Operating Segments Not Included In Reportable Segments And Other Revenue Generating Business Activitiesother segments | segment profit | 2022-04-01 → 2023-03-31 | ¥257m |
| Reconciling Itemsreconciling | capex | 2022-04-01 → 2023-03-31 | ¥14.0bn |
| Reconciling Itemsreconciling | depreciation | 2022-04-01 → 2023-03-31 | ¥4.6bn |
| Reconciling Itemsreconciling | revenue | 2022-04-01 → 2023-03-31 | −¥38.3bn |
| Reconciling Itemsreconciling | revenue intersegment | 2022-04-01 → 2023-03-31 | −¥38.3bn |
| Reconciling Itemsreconciling | segment assets | at 2023-03-31 | −¥111.7bn |
| Reconciling Itemsreconciling | segment profit | 2022-04-01 → 2023-03-31 | −¥29.5bn |
| Medical Treatment Relatedreportable segment | capex | 2022-04-01 → 2023-03-31 | ¥49.1bn |
| Medical Treatment Relatedreportable segment | depreciation | 2022-04-01 → 2023-03-31 | ¥22.5bn |
| Medical Treatment Relatedreportable segment | employees | at 2023-03-31 | 27220 pure |
| Medical Treatment Relatedreportable segment | revenue | 2022-04-01 → 2023-03-31 | ¥426.1bn |
| Medical Treatment Relatedreportable segment | revenue external | 2022-04-01 → 2023-03-31 | ¥420.0bn |
| Medical Treatment Relatedreportable segment | revenue intersegment | 2022-04-01 → 2023-03-31 | ¥6.1bn |
| Medical Treatment Relatedreportable segment | segment assets | at 2023-03-31 | ¥618.6bn |
| Medical Treatment Relatedreportable segment | segment profit | 2022-04-01 → 2023-03-31 | ¥38.6bn |
| Medicine Relatedreportable segment | capex | 2022-04-01 → 2023-03-31 | ¥23.5bn |
| Medicine Relatedreportable segment | depreciation | 2022-04-01 → 2023-03-31 | ¥13.4bn |
| Medicine Relatedreportable segment | employees | at 2023-03-31 | 7331 pure |
| Medicine Relatedreportable segment | revenue | 2022-04-01 → 2023-03-31 | ¥95.2bn |
| Medicine Relatedreportable segment | revenue external | 2022-04-01 → 2023-03-31 | ¥72.7bn |
| Medicine Relatedreportable segment | revenue intersegment | 2022-04-01 → 2023-03-31 | ¥22.5bn |
| Medicine Relatedreportable segment | segment assets | at 2023-03-31 | ¥221.6bn |
| Medicine Relatedreportable segment | segment profit | 2022-04-01 → 2023-03-31 | ¥5.6bn |
| Pharma Packagingreportable segment | capex | 2022-04-01 → 2023-03-31 | ¥15.7bn |
| Pharma Packagingreportable segment | depreciation | 2022-04-01 → 2023-03-31 | ¥5.5bn |
| Pharma Packagingreportable segment | employees | at 2023-03-31 | 3303 pure |
| Pharma Packagingreportable segment | revenue | 2022-04-01 → 2023-03-31 | ¥57.7bn |
| Pharma Packagingreportable segment | revenue external | 2022-04-01 → 2023-03-31 | ¥51.8bn |
| Pharma Packagingreportable segment | revenue intersegment | 2022-04-01 → 2023-03-31 | ¥6.0bn |
| Pharma Packagingreportable segment | segment assets | at 2023-03-31 | ¥97.2bn |
| Pharma Packagingreportable segment | segment profit | 2022-04-01 → 2023-03-31 | ¥2.7bn |
| —segment total | capex | 2022-04-01 → 2023-03-31 | ¥88.2bn |
| —segment total | depreciation | 2022-04-01 → 2023-03-31 | ¥41.3bn |
| —segment total | revenue | 2022-04-01 → 2023-03-31 | ¥579.0bn |
| —segment total | revenue external | 2022-04-01 → 2023-03-31 | ¥544.4bn |
| —segment total | revenue intersegment | 2022-04-01 → 2023-03-31 | ¥34.6bn |
| —segment total | segment assets | at 2023-03-31 | ¥937.4bn |
| —segment total | segment profit | 2022-04-01 → 2023-03-31 | ¥47.0bn |
| Total Of Reportable Segments And Otherssegment total | capex | 2022-04-01 → 2023-03-31 | ¥88.6bn |
| Total Of Reportable Segments And Otherssegment total | depreciation | 2022-04-01 → 2023-03-31 | ¥41.6bn |
| Total Of Reportable Segments And Otherssegment total | revenue | 2022-04-01 → 2023-03-31 | ¥583.5bn |
| Total Of Reportable Segments And Otherssegment total | revenue external | 2022-04-01 → 2023-03-31 | ¥545.2bn |
| Total Of Reportable Segments And Otherssegment total | revenue intersegment | 2022-04-01 → 2023-03-31 | ¥38.3bn |
| Total Of Reportable Segments And Otherssegment total | segment assets | at 2023-03-31 | ¥1.14T |
| Total Of Reportable Segments And Otherssegment total | segment profit | 2022-04-01 → 2023-03-31 | ¥47.2bn |
| Operating Segments Not Included In Reportable Segments And Other Revenue Generating Business Activitiesother segments | capex | 2021-04-01 → 2022-03-31 | ¥281m |
| Operating Segments Not Included In Reportable Segments And Other Revenue Generating Business Activitiesother segments | depreciation | 2021-04-01 → 2022-03-31 | ¥299m |
| Operating Segments Not Included In Reportable Segments And Other Revenue Generating Business Activitiesother segments | revenue | 2021-04-01 → 2022-03-31 | ¥2.7bn |
| Operating Segments Not Included In Reportable Segments And Other Revenue Generating Business Activitiesother segments | revenue external | 2021-04-01 → 2022-03-31 | ¥559m |
| Operating Segments Not Included In Reportable Segments And Other Revenue Generating Business Activitiesother segments | revenue intersegment | 2021-04-01 → 2022-03-31 | ¥2.1bn |
| Operating Segments Not Included In Reportable Segments And Other Revenue Generating Business Activitiesother segments | segment assets | at 2022-03-31 | ¥158.4bn |
| Operating Segments Not Included In Reportable Segments And Other Revenue Generating Business Activitiesother segments | segment profit | 2021-04-01 → 2022-03-31 | ¥101m |
| Reconciling Itemsreconciling | capex | 2021-04-01 → 2022-03-31 | ¥7.0bn |
| Reconciling Itemsreconciling | depreciation | 2021-04-01 → 2022-03-31 | ¥4.7bn |
| Reconciling Itemsreconciling | revenue | 2021-04-01 → 2022-03-31 | −¥35.2bn |
| Reconciling Itemsreconciling | revenue intersegment | 2021-04-01 → 2022-03-31 | −¥35.2bn |
| Reconciling Itemsreconciling | segment assets | at 2022-03-31 | −¥57.0bn |
| Reconciling Itemsreconciling | segment profit | 2021-04-01 → 2022-03-31 | −¥28.2bn |
| Medical Treatment Relatedreportable segment | capex | 2021-04-01 → 2022-03-31 | ¥56.8bn |
| Medical Treatment Relatedreportable segment | depreciation | 2021-04-01 → 2022-03-31 | ¥20.1bn |
| Medical Treatment Relatedreportable segment | revenue | 2021-04-01 → 2022-03-31 | ¥379.8bn |
| Medical Treatment Relatedreportable segment | revenue external | 2021-04-01 → 2022-03-31 | ¥373.5bn |
| Medical Treatment Relatedreportable segment | revenue intersegment | 2021-04-01 → 2022-03-31 | ¥6.4bn |
| Medical Treatment Relatedreportable segment | segment assets | at 2022-03-31 | ¥541.9bn |
| Medical Treatment Relatedreportable segment | segment profit | 2021-04-01 → 2022-03-31 | ¥39.2bn |
| Medicine Relatedreportable segment | capex | 2021-04-01 → 2022-03-31 | ¥23.4bn |
| Medicine Relatedreportable segment | depreciation | 2021-04-01 → 2022-03-31 | ¥13.4bn |
| Medicine Relatedreportable segment | revenue | 2021-04-01 → 2022-03-31 | ¥95.0bn |
| Medicine Relatedreportable segment | revenue external | 2021-04-01 → 2022-03-31 | ¥74.4bn |
| Medicine Relatedreportable segment | revenue intersegment | 2021-04-01 → 2022-03-31 | ¥20.6bn |
| Medicine Relatedreportable segment | segment assets | at 2022-03-31 | ¥203.7bn |
| Medicine Relatedreportable segment | segment profit | 2021-04-01 → 2022-03-31 | ¥9.8bn |
| Pharma Packagingreportable segment | capex | 2021-04-01 → 2022-03-31 | ¥9.3bn |
| Pharma Packagingreportable segment | depreciation | 2021-04-01 → 2022-03-31 | ¥4.8bn |
| Pharma Packagingreportable segment | revenue | 2021-04-01 → 2022-03-31 | ¥52.5bn |
| Pharma Packagingreportable segment | revenue external | 2021-04-01 → 2022-03-31 | ¥46.4bn |
| Pharma Packagingreportable segment | revenue intersegment | 2021-04-01 → 2022-03-31 | ¥6.1bn |
| Pharma Packagingreportable segment | segment assets | at 2022-03-31 | ¥83.3bn |
| Pharma Packagingreportable segment | segment profit | 2021-04-01 → 2022-03-31 | ¥2.9bn |
| —segment total | capex | 2021-04-01 → 2022-03-31 | ¥89.5bn |
| —segment total | depreciation | 2021-04-01 → 2022-03-31 | ¥38.3bn |
| —segment total | revenue | 2021-04-01 → 2022-03-31 | ¥527.3bn |
| —segment total | revenue external | 2021-04-01 → 2022-03-31 | ¥494.2bn |
| —segment total | revenue intersegment | 2021-04-01 → 2022-03-31 | ¥33.1bn |
| —segment total | segment assets | at 2022-03-31 | ¥828.9bn |
| —segment total | segment profit | 2021-04-01 → 2022-03-31 | ¥52.0bn |
| Total Of Reportable Segments And Otherssegment total | capex | 2021-04-01 → 2022-03-31 | ¥89.8bn |
| Total Of Reportable Segments And Otherssegment total | depreciation | 2021-04-01 → 2022-03-31 | ¥38.6bn |
| Total Of Reportable Segments And Otherssegment total | revenue | 2021-04-01 → 2022-03-31 | ¥530.0bn |
| Total Of Reportable Segments And Otherssegment total | revenue external | 2021-04-01 → 2022-03-31 | ¥494.8bn |
| Total Of Reportable Segments And Otherssegment total | revenue intersegment | 2021-04-01 → 2022-03-31 | ¥35.2bn |
| Total Of Reportable Segments And Otherssegment total | segment assets | at 2022-03-31 | ¥987.3bn |
| Total Of Reportable Segments And Otherssegment total | segment profit | 2021-04-01 → 2022-03-31 | ¥52.1bn |
| Medical Treatment Relatedreportable segment | employees | at 2023-03-31 | 3406 pure |
| Medicine Relatedreportable segment | employees | at 2023-03-31 | 25 pure |
| Pharma Packagingreportable segment | employees | at 2023-03-31 | 161 pure |
Segment names come from EDINET member IDs; not yet mapped to a common taxonomy.
All source rows · 2,116
| Item | Context | Value | Unit |
|---|---|---|---|
| Purchase of investment securities inv cf | Prior1YearDuration | -253000000 | JPY |
| Purchase of investment securities inv cf | CurrentYearDuration | -51000000 | JPY |
| Proceeds from sales of investment securities inv cf | Prior1YearDuration | 262000000 | JPY |
| Proceeds from sales of investment securities inv cf | CurrentYearDuration | 4979000000 | JPY |
| Purchase of investments in subsidiaries inv cf | Prior1YearDuration | -192000000 | JPY |
| Purchase of investments in subsidiaries inv cf | CurrentYearDuration | -952000000 | JPY |
| Purchase of investments in capital of subsidiaries inv cf | Prior1YearDuration | -70000000 | JPY |
| Purchase of investments in capital of subsidiaries inv cf | CurrentYearDuration | － | JPY |
| Proceeds from sales of shares of associates inv cf | Prior1YearDuration | 2845000000 | JPY |
| Proceeds from sales of shares of associates inv cf | CurrentYearDuration | － | JPY |
| Purchase of investments in subsidiaries resulting in change in scope of consolidation inv cf | Prior1YearDuration | -5187000000 | JPY |
| Purchase of investments in subsidiaries resulting in change in scope of consolidation inv cf | CurrentYearDuration | -2076000000 | JPY |
| Payments for transfer of business2 inv cf | Prior1YearDuration | -24000000 | JPY |
| Payments for transfer of business2 inv cf | CurrentYearDuration | -26000000 | JPY |
| Purchase of noncurrent assets inv cf | Prior1YearDuration | -79803000000 | JPY |
| Purchase of noncurrent assets inv cf | CurrentYearDuration | -84835000000 | JPY |
| Proceeds from sales of noncurrent assets inv cf | Prior1YearDuration | 4278000000 | JPY |
| Proceeds from sales of noncurrent assets inv cf | CurrentYearDuration | 10799000000 | JPY |
| Payments for retirement of noncurrent assets inv cf | Prior1YearDuration | -154000000 | JPY |
| Payments for retirement of noncurrent assets inv cf | CurrentYearDuration | -256000000 | JPY |
| Proceeds from governmental subsideies for investment in property and equipment inv cf | Prior1YearDuration | 269000000 | JPY |
| Proceeds from governmental subsideies for investment in property and equipment inv cf | CurrentYearDuration | 10000000 | JPY |
| Net decrease increase in short term loans receivable inv cf | Prior1YearDuration | 295000000 | JPY |
| Net decrease increase in short term loans receivable inv cf | CurrentYearDuration | 23000000 | JPY |
| Payments of loans receivable inv cf | Prior1YearDuration | -360000000 | JPY |
| Payments of loans receivable inv cf | CurrentYearDuration | -140000000 | JPY |
| Collection of loans receivable inv cf | Prior1YearDuration | 7000000 | JPY |
| Collection of loans receivable inv cf | CurrentYearDuration | 216000000 | JPY |
| Other payments inv cf | Prior1YearDuration | -12000000 | JPY |
| Other payments inv cf | CurrentYearDuration | -10000000 | JPY |
| Other proceeds inv cf | Prior1YearDuration | － | JPY |
| Other proceeds inv cf | CurrentYearDuration | 72000000 | JPY |
| Net cash provided by used in investment activities | Prior1YearDuration | -78434000000 | JPY |
| Net cash provided by used in investment activities | CurrentYearDuration | -71737000000 | JPY |
| Net increase decrease in short term loans payable fin cf | Prior1YearDuration | 26860000000 | JPY |
| Net increase decrease in short term loans payable fin cf | CurrentYearDuration | -15116000000 | JPY |
| Net increase decrease in commercial papers fin cf | Prior1YearDuration | － | JPY |
| Net increase decrease in commercial papers fin cf | CurrentYearDuration | 10000000000 | JPY |
| Proceeds from long term loans payable fin cf | Prior1YearDuration | 61470000000 | JPY |
| Proceeds from long term loans payable fin cf | CurrentYearDuration | 115025000000 | JPY |
| Repayment of long term loans payable fin cf | Prior1YearDuration | -100836000000 | JPY |
| Repayment of long term loans payable fin cf | CurrentYearDuration | -74963000000 | JPY |
| Proceeds from issuance of bonds fin cf | Prior1YearDuration | 35245000000 | JPY |
| Proceeds from issuance of bonds fin cf | CurrentYearDuration | － | JPY |
| Redemption of bonds fin cf | Prior1YearDuration | -1600000000 | JPY |
| Redemption of bonds fin cf | CurrentYearDuration | -2200000000 | JPY |
| Proceeds from issuance of common stock fin cf | Prior1YearDuration | － | JPY |
| Proceeds from issuance of common stock fin cf | CurrentYearDuration | 19730000000 | JPY |
| Proceeds from sales of treasury stock fin cf | Prior1YearDuration | 0 | JPY |
| Proceeds from sales of treasury stock fin cf | CurrentYearDuration | 0 | JPY |
Every row of the EDINET CSV. Item names are the XBRL element names; filed text is kept in its original Japanese. Filed text is available on Plus and Pro.
Data checks · 24 of 24 passed
| balance sheet identity | pass rounding |
| balance sheet identity | pass rounding |
| balance sheet identity | pass rounding |
| balance sheet identity | pass |
| dei present | pass |
| period resolution | pass |
| statement vs summary · net assets | pass |
| statement vs summary · net assets | pass |
| statement vs summary · net assets | pass |
| statement vs summary · net assets | pass |
| statement vs summary · net assets | pass |
| statement vs summary · net assets | pass |
| statement vs summary · net income attributable to parent | pass |
| statement vs summary · net income attributable to parent | pass |
| statement vs summary · operating cash flow | pass |
| statement vs summary · operating cash flow | pass |
| statement vs summary · revenue | pass |
| statement vs summary · revenue | pass |
| statement vs summary · revenue | pass |
| statement vs summary · revenue | pass |
| statement vs summary · total assets | pass |
| statement vs summary · total assets | pass |
| statement vs summary · total assets | pass |
| statement vs summary · total assets | pass |